<DOC>
	<DOCNO>NCT01884597</DOCNO>
	<brief_summary>This 24-month study ranibizumab ( 2.0 mg 1.0 mg ) subject polypoidal choroidal vasculopathy diagnose fluorescein/indocyanine green ( FA/ICG ) angiography .</brief_summary>
	<brief_title>Investigator Sponsored Trial Polypoidal Choroidal Vasculopathy ( PCV ) Evaluation Assessing High-Dose Ranibizumab Prospectively ( PEARL2 )</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 25 year Polypoidal choroidal vasculopathy note fluorescein ICG angiography : active leakage , active bleeding recent decrease vision BCVA use ETDRS 20/32 20/400 Any history previous vitrectomy Any prior treatment verteporfin photodynamic therapy study eye . Previous cataract surgery within precede 2 month Day 0 Active intraocular inflammation study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure , cardiovascular disease ) Participation investigational trial within 30 day randomization involve treatment drug receive regulatory approval time study entry . Prior antivascular endothelial growth factor ( VEGF ) ( Macugen , Avastin , Lucentis ) study eye prior within 30 day prior enrollment study Known allergy component study drug Blood pressure &gt; 180/110 ( systolic 180 diastolic 110 ) If blood pressure bring 180/110 antihypertensive treatment , patient become eligible . Major surgery within 28 day prior randomization major surgery plan within next 12 month . Major surgery define surgical procedure extensive needle biopsy/aspiration placement central venous access device , removal/biopsy skin lesion , placement peripheral venous catheter . Myocardial infraction , cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 6 month prior randomization . Systemic antiVEGF proVEGF treatment within 3 month prior randomization . History recurrent significant infection bacterial infection Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception , surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicide gel , intra uterine device ( IUD ) , contraceptive hormone implant patch Prior enrollment study Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>PEARL2</keyword>
	<keyword>PCV</keyword>
	<keyword>Polypoidal Choroidal Vasculopathy</keyword>
</DOC>